The FRA1 antibody detects FOS-related antigen 1 (FRA1), a protein encoded by the FOSL1 gene, which belongs to the FOS family of transcription factors. FRA1 forms part of the AP-1 (Activator Protein 1) complex by dimerizing with JUN family proteins, regulating gene expression in response to cellular signals like growth factors, stress, or cytokines. It plays critical roles in cell proliferation, differentiation, apoptosis, and oncogenic transformation. FRA1 is overexpressed in various cancers (e.g., breast, lung, colorectal) and is associated with tumor progression, metastasis, and therapy resistance due to its involvement in epithelial-mesenchymal transition (EMT) and matrix remodeling.
FRA1 antibodies are widely used in research to study its expression, localization, and function via techniques like Western blotting, immunofluorescence, and immunohistochemistry. Specific clones (e.g., E-8. D1D7) vary in reactivity across species (human, mouse, rat) and applications, requiring validation with appropriate controls. Research on FRA1 spans cancer biology, developmental processes, and inflammatory diseases, with emerging links to fibrosis and immune modulation. Its activity is regulated by post-translational modifications (e.g., phosphorylation via ERK/MAPK pathways) and interactions with other transcription cofactors. Studies targeting FRA1 aim to uncover therapeutic strategies for malignancies and chronic diseases.